New research reveals that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt traditional lifestyle plans.
Published data in a major medical journal shows that while obese individuals frequently drop about a fifth of their total mass while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"People using such drugs need to be informed of the risk of quick weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb.
Such speed of recovery suggests a return to starting weight in about a year and a half.
Comparing Approaches
The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the results of these new drugs with other pills.
Researchers note that people who shed pounds through lifestyle changes alone typically experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Experts propose the mode of action of the drugs explains the heightened rebound.
These medications mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations far above than normal might result in the body to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating much more probable."
An Ongoing Condition?
Health authorities advise the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
Professionals argue that, due to the high risk of weight regain, the therapy should be considered long-term.
This opinion is reinforced by drug manufacturers, who say that the results "emphasize the persistent nature of excess weight," akin to managing diseases like high blood pressure.
User Testimonies
Individuals who have come off the medication describe a sudden resurgence of cravings.
"I experienced a switch activating and I was suddenly extremely hungry," recalled an individual.
This difficulty is exacerbated if users have not developed permanent dietary or behavioural modifications during therapy.
Widespread Interest
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Use is greater among women than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are potent agents for weight loss, they are not a permanent solution and maintained weight loss likely depends on ongoing behavioural support.
